Oral contraceptives, thrombosis and haemostasis

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 95, Issue 2, 2001, Pages 193-197

  Rosing, Jan ^a   Curvers, Joyce ^a   Tans, Guido ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

APC resistance; Factor V Leiden; Oral contraceptives; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5A; DESOGESTREL; FIBRIN; GESTODENE; ORAL CONTRACEPTIVE AGENT; PROTEIN S; PROTHROMBIN; SERINE PROTEINASE; THROMBIN; THROMBOPLASTIN;

CONFERENCE PAPER; DRUG ACTIVITY; FEMALE; FIBRINOLYSIS; GENE MUTATION; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; RISK FACTOR; VEIN THROMBOSIS;

EID: 0035068717     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(00)00489-9     Document Type: Conference Paper

References (37)

1. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
2. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen
3. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women
4. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women
5. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
6. The 1995 pill scare revisited: anatomy of a non-epidemic
7. Classification and comparison of oral contraceptives containing new generation progestagens
8. Oral contraceptives and venous thromboembolism
9. Effects of oral contraceptives on haemostasis variables
10. Resistance to activated protein C in healthy women taking oral contraceptives
11. Sensitivity to activated protein C; influence of oral contraceptives and sex
12. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
13. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C
14. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study
15. Resistance to activated protein C as a basis for venous thrombosis
16. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
17. Mutation in blood coagulation factor V associated with resistance to activated protein C
18. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V
19. Activated protein C resistance caused by Arg506Gln mutation in factor Va
20. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
21. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
22. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals
23. The 1995 pill scare revisited: anatomy of a non-epidemic
24. Blood coagulation and oral contraceptives. A critical review
25. Oral contraceptives and venous thromboembolism: acquired APC resistance?
26. Bias versus causality: interpreting recent evidence of oral contraceptive studies
27. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study
28. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism
29. APC resistance determined with the endogenous thrombin potential is associated with venous thrombosis: a blinded clinical evaluation
30. Oral contraceptives and venous thromboembolism
31. Acquired activated protein-C resistance in pregnancy and association with increased thrombin generation and fetal weight
32. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study
33. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways
34. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives
35. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
36. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation